SUNRISE, Fla., Feb. 14 /PRNewswire/ -- Bioheart, Inc. announced today that it filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in this offering will be offered by the Company.
BMO Capital Markets Corp. will act as sole book-running manager of the proposed offering. Janney Montgomery Scott, LLC and Merriman Curhan Ford & Co. will act as co-lead manager and co-manager of the proposed offering, respectively. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this proposed offering may be obtained from the Securities and Exchange Commission website at www.sec.gov or by contacting BMO Capital Markets Corp. c/o Equity Syndicate Desk, 3 Times Square, New York, NY 10036, Attention: Lori Begley at (212) 885-4039 or Kate Kennedy at (212) 885-4032.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Cautionary Statement
This press release contains forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this press release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
About Bioheart
Bioheart, Inc. is a biotechnology company focused on the discovery, development and commercialization of therapies using cells derived from a patient's body, and related devices, for the treatment of heart damage. Bioheart's lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient's heart with living muscle tissue for the purpose of improving cardiac function. Bioheart is currently testing MyoCell for treatment of severe, non-acute damage to the heart in patients in Class II or Class III heart failure according to the New York Heart Association heart failure classification system.
Bioheart, Inc.CONTACT: William H. Kline, Chief Financial Officer of Bioheart, Inc.,+1-954-835-1500
Web site: http://www.bioheartinc.com/
